(LLY) Eli Lilly and Company Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LLY) Eli Lilly and Company Bundle
Eli Lilly’s Business Model: A Clear Blueprint for Value Creation
Unlock the strategic blueprint behind Eli Lilly and Company’s business model. This concise Business Model Canvas highlights how Lilly creates value through breakthrough medicines, strong partnerships, and a global commercial footprint. Perfect for investors, analysts, and strategists who want a clear edge—download the full version for deeper insights.
Partnerships
Boehringer Ingelheim diabetes alliance
Boehringer Ingelheim and Eli Lilly and Company co-developed and co-commercialized diabetes therapies, including Jardiance, which generated $7.8 billion in worldwide sales in 2024. The alliance expands access to type 2 diabetes medicines in multiple markets and lets Eli Lilly and Company share development and launch risk while keeping a major profit pool in a large therapy area.
Incyte oncology collaboration
Incyte gives Eli Lilly and Company external oncology depth by pairing Lilly’s commercialization scale with Incyte’s cancer research engine, helping push more than one pipeline path at once. That matters because Eli Lilly and Company can spread risk beyond internal discovery and move faster into new tumor settings.
AbCellera antibody discovery partnership
Lilly's antibody discovery partnership with AbCellera speeds early hit-finding by pairing high-throughput single-cell screening with biologics development. It is especially useful for infectious disease and immunology programs, where faster antibody ID can shorten early research cycles and improve candidate selection.
Junshi Biosciences and Tyvyt access
Junshi Biosciences gives Eli Lilly and Company a local route to complex oncology commercialization in China, where cancer burden is huge: 4.8 million new cases were estimated in 2022. That can widen access for selected cancer assets and speed regional launch work in large Asian markets.
- Local cancer access in China
- Supports oncology commercialization
- Extends reach in Asia
Biotech research partners including Foghorn and Lycia
Eli Lilly and Company uses biotech partners like Foghorn and Lycia to tap platform tech and discovery tools that help find novel targets and mechanisms. That matters for pipeline spread across multiple therapeutic areas, and it fits Lilly’s 2025-scale R&D push of 10+ late-stage programs across oncology, immunology, and neuroscience.
- Platform tech speeds target discovery
- Expands novel mechanism sourcing
- Supports pipeline diversification
Lilly’s Partnerships Expand Pipeline and Reduce R&D Risk
Eli Lilly and Company's key partnerships widen pipeline reach and cut R&D risk. Boehringer Ingelheim, Incyte, and AbCellera add diabetes, oncology, and antibody discovery scale, while Junshi, Foghorn, and Lycia support China access and new target work.
| Partner | Value |
|---|---|
| Boehringer Ingelheim | Jardiance sold $7.8B in 2024 |
| AbCellera | Speeds antibody hit finding |
What is included in the product
Detailed Word Document
A concise Business Model Canvas capturing Eli Lilly’s pharma strategy, key customers, channels, partnerships, and value creation.
Customizable Excel Spreadsheet
Eli Lilly’s Business Model Canvas quickly clarifies its value drivers, easing strategy gaps and decision-making pain points.
Reference Sources
Cites credible sources behind Eli Lilly and Company data, making the analysis easier to trust, verify, and use for decisions.
Activities
Drug discovery and preclinical research
Lilly’s drug discovery and preclinical research is the first step in its multi-therapy pipeline, with heavy work across diabetes, oncology, immunology, neuroscience, and pain. In 2025, Lilly spent about $11 billion on R&D, backing biology, chemistry, and translational science that turn early ideas into testable candidates.
Clinical development and trials
Eli Lilly and Company runs Phase 1 to Phase 3 trials to prove safety and efficacy for new medicines and label expansions, and that evidence is what drives FDA approval and payer uptake. In 2024, the Company spent about $11.0 billion on R&D, showing how clinical development is a long-cycle, capital-heavy activity.
Regulatory submissions and approvals
Eli Lilly and Company files and defends global submissions with the FDA, EMA, and other regulators to win first approvals, line extensions, and new indications. In 2025, R&D spend reached about $13.5 billion, and that work supports a pipeline with 13+ phase 3 programs, where each filing can shape a launch worth billions.
Manufacturing and quality control
Eli Lilly and Company runs large-scale manufacturing for sterile biologics, small molecules, and injectables, where tight quality control is non-negotiable because one failed batch can hit patient safety and supply. In 2025, this activity underpinned Lilly’s global launch supply as demand for its medicines kept rising.
- Produces complex drugs at industrial scale
- Uses strict quality systems
- Protects safety, consistency, and supply
Commercialization and lifecycle management
Eli Lilly and Company commercializes established brands while pushing new launches, then extends value with new indications, formulations, and market expansion. That matters: Lilly reported 2024 revenue of $45.0 billion, and lifecycle moves help defend that base after launch.
- Launch new brands fast
- Add indications and formulations
- Expand into more markets
- Protect sales after launch
Eli Lilly’s $13.5B R&D Engine Powers Its Global Growth Pipeline
Eli Lilly and Company’s key activities center on discovery, late-stage trials, and regulatory filings, with 2025 R&D at about $13.5 billion to fund its diabetes, oncology, immunology, and neuroscience pipeline. The Company also runs high-volume sterile and small-molecule manufacturing, where quality control protects supply for global launches.
| Activity | 2025 data |
|---|---|
| R&D | About $13.5B |
| Phase 3 pipeline | 13+ programs |
| Manufacturing | Global launch supply |
Preview Before You Purchase
Business Model Canvas
This Eli Lilly and Company Business Model Canvas preview is the exact document you will receive after purchase. It is not a sample or mockup—the file shown here is a direct preview of the final deliverable. Once your order is complete, you’ll get this same professionally formatted document in full, ready to use, edit, or present.
Resources
Broad branded medicine portfolio
Lilly’s broad branded portfolio spans 9 major medicines—Humalog, Jardiance, Trulicity, Verzenio, Taltz, Emgality, Zyprexa, Cialis, and Forteo—across diabetes, oncology, immunology, migraine, mental health, and bone health. In 2025, chronic-care brands like Jardiance and specialty franchises like Verzenio kept recurring demand and helped support multi-billion-dollar sales.
Global R and D capabilities
Eli Lilly and Company spent more than $13 billion on R&D in 2025, backing global labs, trial teams, and development systems that turn discoveries into approved medicines. That scale makes global R&D a core asset: it feeds the pipeline, speeds regulatory work, and supports long-term growth.
Intellectual property and patents
Eli Lilly and Company’s patents and other IP are core assets because they protect drug molecules, formulations, and manufacturing know-how, helping preserve exclusivity and pricing power. In 2024, Eli Lilly and Company invested $11.0 billion in R&D, a scale that depends on strong patent protection to defend launches like tirzepatide-based therapies.
Manufacturing network and supply chain
Eli Lilly and Company is backing its manufacturing network with more than $50 billion of planned U.S. investment through 2029, including four new sites, because plants, quality systems, and logistics are core to global medicine and biologics supply. In 2025, this footprint is a key guardrail for continuity of supply and faster distribution.
- More than $50 billion planned
- Four new U.S. sites
- Supports global drug supply
- Reduces shortage risk
Regulatory, medical, and commercial expertise
Eli Lilly and Company leans on regulatory, medical, sales, and market-access talent to turn approvals into uptake. That matters in 2025 for therapies with about $1,000-a-month list prices, where physician education and payer coverage can decide volume.
- Supports FDA approvals and label strategy
- Drives physician and patient education
- Secures payer access and reimbursement
Eli Lilly’s $13B R&D and $50B U.S. buildout fuel growth
Eli Lilly and Company’s key resources are its branded drug portfolio, deep R&D engine, and protected IP. In 2025, R&D topped $13 billion, while more than $50 billion of planned U.S. investment through 2029 is expanding manufacturing capacity and supply security.
| Key resource | 2025/2026 data |
|---|---|
| R&D spend | More than $13 billion |
| Planned U.S. capex | More than $50 billion through 2029 |
| New sites | Four |
Value Propositions
Large diabetes treatment portfolio
Lilly’s diabetes portfolio spans legacy insulins and newer therapies, giving prescribers more choices for glycemic control across different patient needs. In 2025, Mounjaro generated about $11.5 billion in sales, and Lilly’s total revenue was about $45 billion, showing the scale of this franchise.
Oncology medicines across multiple cancers
Eli Lilly and Company covers 6 major cancer areas—breast, colorectal, lung, gastric, thyroid, and others—so it can support complex treatment paths across both early and advanced disease. That breadth makes the oncology offer relevant at multiple stages of care, not just one point in the patient journey.
Specialty care in immunology and inflammation
Lilly’s specialty care in immunology and inflammation centers on 2 core brands, Taltz and Olumiant, which target immune-mediated diseases with more precise treatment options. These medicines serve patients with chronic inflammatory conditions across multiple approved indications, including plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and alopecia areata.
Neuroscience and pain solutions
Eli Lilly and Company uses neuroscience and pain drugs like Cymbalta, Emgality, and Zyprexa to treat depression, migraine, and serious psychiatric care, supporting long-term use. Lilly reported $45.0B in 2024 revenue, and this portfolio helps reduce reliance on metabolic and cancer growth alone.
- Depression, migraine, psychiatry
- Long-term patient management
- Broadens revenue mix
Global human-medicine expertise
Lilly’s value is global human-medicine expertise: it discovers, develops, and sells medicines across diabetes, obesity, oncology, and immunology, with 2025 revenue near $60 billion after $45.0 billion in 2024. That scale helps keep drugs available in more markets and gives physicians confidence in a broad, single-source portfolio.
- 2025 revenue: about $60 billion
- 2024 revenue: $45.0 billion
- Broad coverage: diabetes to oncology
- Global scale supports access
Lilly’s Broad Patent Power Drives $60B in Revenue
Eli Lilly and Company’s value proposition is broad, patented medicine coverage across diabetes, obesity, oncology, immunology, and neuroscience, with 2025 revenue near $60 billion and 2024 revenue of $45.0 billion. Its scale helps Lilly serve more patient groups with one global brand.
| Metric | Value |
|---|---|
| 2025 revenue | About $60B |
| 2024 revenue | $45.0B |
| Core areas | 5 major therapy groups |
Customer Relationships
Physician and specialist engagement
Eli Lilly and Company builds tight ties with endocrinologists, oncologists, rheumatologists, neurologists, and psychiatrists, and these key opinion leader links help shape prescribing and treatment choice. In 2024, Eli Lilly and Company reported $45.0 billion in revenue, with growth driven by specialty drugs where medical education and peer-to-peer science matter most.
Patient support and adherence programs
Eli Lilly and Company supports patients with education, access tools, and therapy-management resources, which matters in chronic care: about 38.4 million people in the U.S. live with diabetes, and many autoimmune patients need long-term adherence. These programs can improve persistence, outcomes, and repeat use of Lilly therapies.
Healthcare payer and formulary management
In 2025, Lilly kept insurer, PBM, and government-buyer talks central as access for high-cost drugs like Zepbound and Mounjaro shaped sales and patient affordability. With list prices near $1,000 a month, formulary placement can decide whether coverage is broad or tightly limited.
Medical affairs and evidence support
Eli Lilly and Company’s medical affairs team supports clinicians with clinical, safety, and real-world evidence so they can choose the right treatment for each patient. This relationship is built on efficacy, safety, and post-market data, which helps reduce misuse and supports informed prescribing.
- Clinical data backs appropriate use
- Safety and real-world evidence guide care
- Helps clinicians make faster decisions
Specialty pharmacy coordination
Lilly uses specialty pharmacies to control fulfillment and onboard patients for complex therapies, which matters for drugs that need education and close follow-up. In 2025, Lilly kept scaling high-demand specialty brands like Zepbound and Mounjaro, and specialty-channel coordination helps move these therapies faster while keeping access and support tight.
- Controlled distribution
- Patient onboarding and education
- Better access for complex therapies
Eli Lilly’s Growth Hinges on Prescribers, Payers, and Patient Support
Eli Lilly and Company’s customer ties are built on prescribers, payers, and patients: in 2025, revenue rose on demand for Zepbound and Mounjaro, while access talks with insurers and PBMs kept shaping uptake. Patient support, medical affairs, and specialty pharmacy coordination help drive adherence in long-term care.
| Channel | Role | Data |
|---|---|---|
| Prescribers | Clinical trust | 2025 growth led by specialty drugs |
| Payers | Coverage access | List prices near 1000/month |
| Patients | Support and adherence | 38.4M US people live with diabetes |
Channels
Hospitals and oncology centers
Hospitals and oncology centers are a core channel for Eli Lilly and Company because many cancer medicines are given by infusion or need specialist supervision. These sites also drive prescribing for advanced oncology care, where access to hospital-based teams shapes treatment choice and patient flow.
Retail and specialty pharmacies
Retail and specialty pharmacies are a key route for Eli Lilly and Company’s diabetes, neuroscience, and other chronic therapies, with Lilly reporting $45.0 billion in 2024 revenue. Specialty pharmacies also support higher-touch products with refill help, training, and patient support, which can improve persistence and widen access.
Wholesalers and distributors
Eli Lilly and Company uses wholesalers and distributors to move medicines to providers and pharmacies, which supports national and global reach and tighter inventory control. In 2024, Lilly reported $45.0 billion in revenue, and this channel helped keep high-volume products flowing through large U.S. and international networks.
Direct sales and medical representative teams
Eli Lilly and Company uses direct sales and medical representative teams to meet clinicians and hospital buyers face to face, explain dosing, and present clinical data that drives brand uptake. This channel matters because Lilly’s 2025 growth was still led by key in-person promoted products like Mounjaro and Zepbound.
- Direct clinician outreach
- Shares trial evidence
- Supports faster adoption
Digital and patient access platforms
Digital and patient access platforms help patients learn about Eli Lilly and Company therapies, check coverage, and use support tools, while prescribers and caregivers get dosing and access guidance. In 2025, Eli Lilly and Company posted $45.0 billion in revenue, and these digital channels help extend that reach beyond in-person sales.
- Supports patient education and access
- Helps prescribers and caregivers
- Complements field sales and clinics
How Eli Lilly Gets Mounjaro and Zepbound to Patients
Eli Lilly and Company sells through hospitals, specialty pharmacies, wholesalers, and field teams, with digital support layering on access and education. In 2025, revenue reached $45.0 billion, and these channels helped move high-demand drugs like Mounjaro and Zepbound across clinic, pharmacy, and patient touchpoints.
| Channel | Role |
|---|---|
| Hospitals and specialty pharmacies | Access for infusion and chronic care |
| Wholesalers, reps, digital tools | Scale, adoption, and patient support |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.